US Pharma MarketingAstraZeneca is getting rights to a Sino Biopharmaceutical drug that offers a dual mechanism to treat chronic obstructive pulmonary disease, or COPD. It’s the same approach as an FDA-approved drug that Merck acquired last year in a multi-billion dollar deal. Toggle Search Close navigation News Health Tech BioPharma Devices & Diagnostics Consumer / Employer Contributors MedCity Influencers Events Bullseye INVEST Digital Health Podcasts Research Spotlight Payer Challenges and Opportunities Newsletters Newsletter Signup Send Tips Webinars eBooks Twitter Facebook TikTok YouTube LinkedIn RSS Subscribe via email Search for: Search BioPharma, Pharma AstraZeneca Turns to China for Molecule That Might Top New…
AstraZeneca is getting rights to a Sino Biopharmaceutical drug that offers a dual mechanism to treat chronic obstructive pulmonary disease, or COPD. It’s the same approach as an FDA-approved drug that Merck acquired last year in a multi-billion dollar deal.
The post AstraZeneca Turns to China for Molecule That Might Top New Merck COPD Drug appeared first on MedCity News.
Source: MedCity News